CARDIOPROTECTIVE POTENTIAL OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS

被引:2
作者
GAVRAS, I [1 ]
GAVRAS, H [1 ]
机构
[1] BOSTON UNIV, SCH MED,HYPERTENS & ATHEROSCLEROSIS SECT, 80 E CONCORD ST,ROOM L217, BOSTON, MA 02118 USA
关键词
CORONARY RISK FACTORS; HEMODYNAMICS OF ACE INHIBITION; METABOLIC CONSEQUENCES OF ACE INHIBITION; BRADYKININ; ISCHEMIA; CARDIOMYOPATHY;
D O I
10.1002/clc.4960141811
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Antihypertensive drugs have various effects, both positive and negative, on metabolic and hemodynamic risk factors for coronary artery disease. Cardioprotective effects of angiotensin-converting enzyme (ACE) inhibitors have recently been described. The benefits of ACE inhibition include not only a reduction in blood pressure but also improved insulin responsiveness, prevention of potassium loss, diminished myocardial oxygen demand, suppression of catecholamines, and interaction with bradykinin and prostaglandins. These benefits result in improved perfusion of vital organs, diminished cardiac work, and protection of coronary vessels, evident in improved left ventricular systolic and diastolic function, elevation of the anginal threshold in ischemic heart disease, and decreased morbidity and mortality in congestive heart failure.
引用
收藏
页码:68 / 71
页数:4
相关论文
共 33 条
[1]   VASODEPRESSOR ROLE OF ENDOGENOUS BRADYKININ ASSESSED BY A BRADYKININ ANTAGONIST [J].
BENETOS, A ;
GAVRAS, H ;
STEWART, JM ;
VAVREK, RJ ;
HATINOGLOU, S ;
GAVRAS, I .
HYPERTENSION, 1986, 8 (11) :971-974
[2]   ROLE OF KININS IN THE ACUTE ANTIHYPERTENSIVE EFFECT OF THE CONVERTING ENZYME-INHIBITOR, CAPTOPRIL [J].
CARRETERO, OA ;
MIYAZAKI, S ;
SCICLI, AG .
HYPERTENSION, 1981, 3 (01) :18-22
[3]  
Chen X, 1989, Prog Clin Biol Res, V301, P167
[4]   ANTIATHEROGENIC EFFECT OF CAPTOPRIL IN THE WATANABE HERITABLE HYPERLIPIDEMIC RABBIT [J].
CHOBANIAN, AV ;
HAUDENSCHILD, CC ;
NICKERSON, C ;
DRAGO, R .
HYPERTENSION, 1990, 15 (03) :327-331
[5]  
CLELAND JGF, 1984, SCOT MED J, V29, P129
[6]  
DELANGEN CDJ, 1987, PROSTACYCLIN ITS STA, P205
[7]   LIMITATION OF EXPERIMENTAL INFARCT SIZE BY AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR [J].
ERTL, G ;
KLONER, RA ;
ALEXANDER, RW ;
BRAUNWALD, E .
CIRCULATION, 1982, 65 (01) :40-48
[8]   DIRECT MYOCARDIAL AND CORONARY EFFECTS OF ENALAPRILAT IN PATIENTS WITH DILATED CARDIOMYOPATHY - ASSESSMENT BY A BILATERAL INTRACORONARY INFUSION TECHNIQUE [J].
FOULT, JM ;
TAVOLARO, O ;
ANTONY, I ;
NITENBERG, A .
CIRCULATION, 1988, 77 (02) :337-344
[9]  
GAVRAS H, 1971, LANCET, V2, P19
[10]   ANGIOTENSIN CONVERTING ENZYME-INHIBITION IN PATIENTS WITH CONGESTIVE HEART-FAILURE [J].
GAVRAS, H ;
FAXON, DP ;
BERKOBEN, J ;
BRUNNER, HR ;
RYAN, TJ .
CIRCULATION, 1978, 58 (05) :770-776